Literature DB >> 27776599

Comparative utility of interferon-γ release assay, QuantiFERON® TB-GIT and T-SPOT®.TB in rheumatoid arthritis.

R Matsumura1, H Igari2, T Nakazawa1, S Ishikawa3, M Tsuyuzaki4, K Suzuki4, F Yamagishi3.   

Abstract

SETTING: National hospital for tuberculosis (TB) and rheumatoid arthritis (RA) in Japan.
OBJECTIVE: To compare two interferon-γ release assays (IGRAs), QuantiFERON®-TB Gold In-Tube (QFT) and T-SPOT®.TB (T-SPOT), in RA patients for detecting latent tuberculous infection (LTBI).
DESIGN: QFT and T-SPOT were conducted concurrently in 230 prospectively enrolled RA patients.
RESULTS: There were no active TB patients. The percentage of QFT- and T-SPOT-positive patients was respectively 8.3% and 5.7%. In patients aged ⩾60 years, these proportions were respectively 12.3% and 7.2%. The percentage of QFT positivity and T-SPOT positivity at age <60 years was respectively 2.2% and 3.3%. After multivariate logistic analysis for QFT positivity, age ⩾60 years and TB suspected based on chest X-ray were selected as independent factors, with adjusted odds ratios of respectively 4.73 and 3.25. No factors were selected for T-SPOT positivity.
CONCLUSION: QFT had a higher positivity rate. In the light of the previous estimated rate of LTBI in Japan, both IGRAs underestimate LTBI, and neither IGRA has enough capability to detect LTBI.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27776599     DOI: 10.5588/ijtld.16.0038

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  2 in total

1.  Human T-cell leukemia virus type 1 may invalidate T-SPOT.TB assay results in rheumatoid arthritis patients: A retrospective case-control observational study.

Authors:  Kunihiko Umekita; Yayoi Hashiba; Kosho Iwao; Chihiro Iwao; Masatoshi Kimura; Yumi Kariya; Kazuyoshi Kubo; Shunichi Miyauchi; Risa Kudou; Yuki Rikitake; Katoko Takajo; Takeshi Kawaguchi; Motohiro Matsuda; Ichiro Takajo; Eisuke Inoue; Toshihiko Hidaka; Akihiko Okayama
Journal:  PLoS One       Date:  2020-05-27       Impact factor: 3.240

Review 2.  Position statement of the Spanish Society of Pediatric Rheumatology on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies: Part 1 (screening).

Authors:  Esmeralda Núñez Cuadros; Joan Calzada-Hernández; Daniel Clemente; Sara Guillén Martín; Laura Fernández Silveira; María José Lirola-Cruz; Alfredo Tagarro; Marisol Camacho Lovillo; Rosa María Alcobendas Rueda; Agustín López López; Miren Satrustegi Aritziturri; Cristina Calvo
Journal:  Eur J Pediatr       Date:  2022-03-08       Impact factor: 3.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.